DUSP6 and melanoma: We further validated inhibition of DUSP6 upon DTP phase across independent set of lapatinib treated HER2+ cells including BT474Br, and two cell lines (EFM192A, HCC1419) from (Data ref: Chang et al, 2022) (GSE155342), or NSCLC, melanoma, and colorectal cancer cells de novo treated with various TKIs (Fig. 3B).